Oxford Biomedica plc (OXB) is a leading biotechnology business based in the UK. It opened the day at 929p after a previous close of 924p. During the day the price has varied from a low of 908.6446p to a high of 942p. The latest price was 923p (25 minute delay). Oxford Biomedica is listed on the London Stock Exchange (LSE) and employs 584 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Oxford Biomedica's share price has had significant positive movement.
Its last market close was 812p, which is 15.64% up on its pre-crash value of 685p and 127.62% up on the lowest point reached during the March crash when the shares fell as low as 356.729p.
If you had bought £1,000 worth of Oxford Biomedica shares at the start of February 2020, those shares would have been worth £873.55 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,351.09.
|52-week range||356.729p - 1025.626p|
|50-day moving average||875.0588p|
|200-day moving average||828.2042p|
|Wall St. target price||1085.99p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-11.6p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-08)||-5.91%|
|1 month (2020-12-17)||-0.11%|
|3 months (2020-10-16)||13.67%|
|6 months (2020-07-17)||7.08%|
|1 year (2020-01-17)||35.94%|
|2 years (2019-01-17)||50.13%|
|3 years (2018-01-17)||89.33%|
|5 years (2016-01-15)||144.18%|
|Revenue TTM||£65.9 million|
|Gross profit TTM||£28.3 million|
|Return on assets TTM||-5.51%|
|Return on equity TTM||-13.31%|
|Market capitalisation||£822.3 million|
TTM: trailing 12 months
We're not expecting Oxford Biomedica to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Oxford Biomedica's shares were split on a 1:50 basis on 30 May 2018. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oxford Biomedica shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Oxford Biomedica shares which in turn could have impacted Oxford Biomedica's share price.
Over the last 12 months, Oxford Biomedica's shares have ranged in value from as little as 356.729p up to 1025.626p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Oxford Biomedica's is 0.4982. This would suggest that Oxford Biomedica's shares are less volatile than average (for this exchange).
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Find out the cheapest way to buy shares on Asia’s largest stock exchange.
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ever wondered how to buy shares in Van Elle Holdings? We explain how and compare a range of providers that can give you access to many brands, including Van Elle Holdings.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.